FMP
NASDAQ
3.27 USD
0.19 (5.81%)
Dr. Todd C. Brady M.D., Ph.D.
Healthcare
Biotechnology
https://www.aldeyra.com
NASDAQ
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for ...
0001341235
US01438T1060
01438T106
131 Hartwell Avenue
781 761 4904
US
10
May 2, 2014
0001341235
NASDAQ
Biotechnology
Healthcare
01438T106
US01438T1060
US
3.27
1.52
501.33k
192.59M
-
1.42-11.97
2.16
-
-
-
-
-5.11
-
https://www.aldeyra.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.